Tocilizumab, a monoclonal antibody that blocks the IL-6 receptor, represents a promising intervention avenue for VEXAS due to its ability to disrupt IL-6-mediated inflammatory processes. The gene discussed is IL6; the disease is VEXAS syndrome.